AstraZeneca presented new data on TAGRISSO® (osimertinib) at the European Lung Cancer Congress (ELCC) 2025, reinforcing its ...

Tagrisso is associated with positive outcomes among patients with unresectable stage 3 EGFR-mutant non-small cell lung cancer ...

The latest data from Johnson and Johnson's Rybrevant and Lazcluze lung cancer combo was better than standard of care Tagrisso ...

Study investigators expect that J&J's combo drug can extend overall survival by at least a year over the current standard of ...

Johnson & Johnson has produced the most convincing data to date that its combination of Rybrevant and Lazcluze could replace ...

Results from multiple clinical trials showed that Tagrisso demonstrated survival benefits in EGFR-mutated non-small cell lung ...

First-line Rybrevant plus Lazcluze significantly extended overall survival versus Tagrisso in mutated, advanced or metastatic non-small cell lung cancer.

OS for osimertinib vs placebo was 58.8 vs 54 months at the latest analysis of the phase 3 LAURA trial, according to ...

New study results presented at the European Lung Cancer Congress 2025, March 26 to 29, demonstrate the role of AstraZeneca’s ...

First approved by the US Food and Drug Administration in 2015, Tagrisso is the dominant lung cancer treatment on the market with nearly $7 billion in annual revenue. J&J’s therapy won US ...

We are excited to see this progress for patients with EGFR-mutated lung cancer, where there is still significant unmet need.” TAGRISSO continued to demonstrate encouraging overall survival (OS ...

(AZN.L, AZN) announced that new study results presented at the European Lung Cancer Congress (ELCC) 2025, demonstrated the role of the company's TAGRISSO (osimertinib), as monotherapy and as the ...